S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Skull found in '97 in remote Alaska belongs to New York man
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Treasury makes more electric SUVs eligible for tax credits
Why a new Alzheimer's drug is having a slow US debut
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Skull found in '97 in remote Alaska belongs to New York man
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Treasury makes more electric SUVs eligible for tax credits
Why a new Alzheimer's drug is having a slow US debut
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Skull found in '97 in remote Alaska belongs to New York man
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Treasury makes more electric SUVs eligible for tax credits
Why a new Alzheimer's drug is having a slow US debut
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Skull found in '97 in remote Alaska belongs to New York man
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Treasury makes more electric SUVs eligible for tax credits
Why a new Alzheimer's drug is having a slow US debut
NASDAQ:WVE

Wave Life Sciences - WVE Stock Forecast, Price & News

$5.15
-0.05 (-0.96%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.05
$5.33
50-Day Range
$3.61
$7.00
52-Week Range
$1.16
$7.12
Volume
337,960 shs
Average Volume
483,804 shs
Market Capitalization
$447.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Wave Life Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
29.4% Upside
$6.67 Price Target
Short Interest
Healthy
1.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.01) to ($1.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

196th out of 1,028 stocks

Pharmaceutical Preparations Industry

89th out of 501 stocks

WVE stock logo

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
WVE.A - | Stock Price & Latest News | Reuters
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
H.C. Wainwright Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
Atlas-backed gene-silencing startup winds down
WVE Wave Life Sciences Ltd.
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings
11/10/2022
Today
2/04/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Employees
235
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+29.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-122,250,000.00
Net Margins
-3,662.25%
Pretax Margin
-3,667.14%

Debt

Sales & Book Value

Annual Sales
$40.96 million
Book Value
$0.55 per share

Miscellaneous

Free Float
58,919,000
Market Cap
$447.54 million
Optionable
Optionable
Beta
-0.96

Key Executives

  • Paul B. Bolno
    President, Chief Executive Officer & Director
  • Kyle Moran
    Chief Financial & Accounting Officer
  • Chandra Vargeese
    Chief Technology Officer
  • Christopher Francis
    SVP-Corporate Development & Head-Emerging Areas
  • Anne-Marie Li-Kwai-Cheung
    Chief Development Officer













WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price forecast for 2023?

3 analysts have issued 1 year target prices for Wave Life Sciences' shares. Their WVE share price forecasts range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2023?

Wave Life Sciences' stock was trading at $7.00 at the beginning of the year. Since then, WVE shares have decreased by 26.4% and is now trading at $5.15.
View the best growth stocks for 2023 here
.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our WVE earnings forecast
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. The firm had revenue of $0.29 million for the quarter, compared to analysts' expectations of $5.48 million. Wave Life Sciences had a negative net margin of 3,662.25% and a negative trailing twelve-month return on equity of 1,038.84%.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DekaBank Deutsche Girozentrale (0.04%), Matisse Capital (0.01%), Matisse Capital (0.01%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Michael A Panzara, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $5.15.

How much money does Wave Life Sciences make?

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $447.54 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does Wave Life Sciences have?

The company employs 235 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 2/4/2023 by MarketBeat.com Staff